Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart Inc (NQ: VXRT )

3.520 +0.040 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,740,886
Open 3.450
Bid (Size) 3.490 (20)
Ask (Size) 3.520 (50)
Prev. Close 3.480
Today's Range 3.315 - 3.595
52wk Range 2.490 - 10.33
Shares Outstanding 126,445,811
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga

Performance

YTD
-46.99%
-46.99%
1 Month
-3.30%
-3.30%
3 Month
-32.70%
-32.70%
6 Month
-45.51%
-45.51%
1 Year
-59.68%
-59.68%

More News

Read More
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Recap: Vaxart Q4 Earnings
Via Benzinga
Vaxart Stock Crosses 2 Key Levels Friday: What's Next?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Vaxart Stock Breaks Out Of Pennant Pattern: Now What?
Via Benzinga
Why Vaxart Stock Is About Ready To See A Breakout
Via Benzinga
Vaxart Stock Is Being Squeezed At The End Of A Pattern
Via Benzinga
3 Stocks That Have Analysts Running for the Exit
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
Via Benzinga
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
Via InvestorPlace
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Via Talk Markets
Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine
Via InvestorPlace
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron
Via Benzinga
VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down
Via InvestorPlace
Cramer Gives His Opinion On Nokia, Delta Air Lines And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
Via Benzinga
Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance
Via InvestorPlace
Exposures COVID-19
Can This COVID Vaccine Stock Help Make You Rich?
Via The Motley Fool
Exposures COVID-19
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.